CBX-12 consists of the pH-sensitive peptide, a self-immolating linker, and the topoisomerase 1 (TOP1) inhibitor exatecan. Methods: In this Phase 1 trial, cohorts of pts were treated with escalating doses of CBX-12 in a 3 + 3 design on three dosing schedules: daily x 5 every 3 weeks, daily x 3 every 3 weeks or once weekly.

Cybrexa has synthesized and developed CBX-12, an alphalexTM conjugate of the potent topoisomerase inhibitor, exatecan. CBX-12 provides additional proof of mechanism to the alphalexTM platform by displaying remarkable tumor-targeting and efficacy in preclinical models.

CBX-12是一种处于临床阶段的FIC多肽偶联药物（PDC），它利用Cybrexa专有的alphalex™技术增强了依喜替康对肿瘤细胞的递送，由pH低插入肽（pHLIP®）、连接体和依沙替康组成。

CBX-12 is a first-in-class PDC that uses Cybrexa’s proprietary alphalex™ technology to enhance the delivery of exatecan, a potent, established topoisomerase 1 (TOP1) inhibitor, directly to tumor cells while sparing healthy tissue.

CBX-12 consists of the pH-sensitive peptide, a self-immolating linker, and the topoisomerase 1 (TOP1) inhibitor exatecan. Method: In a Phase 1 trial, cohorts of patients were treated with escalating doses of CBX-12 in a 3 + 3 design on three dosing schedules: Daily × 5 every 3 weeks (Schedule A), daily × 3 every 3 weeks (Schedule B) or once ...

2021年1月28日 · CBX-12一种新型的实体肿瘤治疗药物，包含一种强效拓扑异构酶I抑制剂效应分子，与抗体药物偶联物（ADC）ENHERTU®和TRODELVY™使用的效应分子属于同一类别。 与这些ADC不同的是，CBX-12能够靶向肿瘤细胞而不依赖于抗原过表达，这将让可及患者群体得到极大扩展。 Cybrexa...

2024年5月29日 · Here we report our new pharmacodynamic (PD) biomarker-driven pilot study of CBX-12 in patients with advanced solid tumors. The primary objective of this study is to assess the effects of CBX-12 on biomarkers of DNA damage response (DDR) in biopsy specimen to establish the degree and duration of CBX-12 target engagement.

CBX-12 is a PDC (peptide drug conjugate) that targets tumors in an antigen-independent manner and exhibits antitumor activity. CBX-12 consists of a pH-sensitive peptide (pHLIP), a self-immolating linker, and a topoisomerase 1 (TOP1) inhibitor Exatecan .

CBX-12 is an alphalex conjugate that includes the highly potent topoisomerase I inhibitor exatecan. CBX-12 was selected based on its ground-breaking efficacy and safety profile demonstrated in preclinical studies. CBX-12 has potential synergy with PD-1 inhibitors and other immuno-oncology drugs.

CBX-12 is an alphalex TM conjugate that includes the highly potent topoisomerase I inhibitor exatecan. CBX-12 has demonstrated strong efficacy and a solid safety profile in preclinical studies.